Melanoma Coverage from Every Angle

Ongoing CE Activities

A 3D Tour of Immuno-Oncology: Melanoma
Adding Oncolytic Virus to Immunotherapy for Advanced Melanoma is Found to be Cost Prohibitive
Advances In™: Metastatic Melanoma: Current Role and Future Potential of Oncolytic Viral Therapy
BRAF/MEK Inhibitor Combo Produces Benefits in Advanced Melanoma
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Community Practice Connections™: Melanoma Tumor Board: Matching Treatment to Patient
Community Practice Connections™: Optimizing Outcomes in Melanoma with BRAF/MEK Inhibitor and Immunotherapeutic Strategies: Essentials for the Onco-Nurse
Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes
First-Line Immune Tx: An Option in V600K-Mutant Melanoma
From IDO to IDON'T: Lessons Learned After a Combo Fails in Advanced Melanoma
Insights & Updates in the Multidisciplinary Treatment of Metastatic Melanoma
Is Mohs Surgery Better Than Traditional Excision for Early-Stage Melanoma?
Monthly Oncology Tumor Boards : A Multidisciplinary Approach To Individualized Patient Care
Multi-Modality Management of Stage IV Melanoma in the Era of Immunotherapy
NCCN Guidelines Insights - Uveal Melanoma Version 1.2019
Oncology Briefings™: How Can Nurses Make the Biggest Impact in Melanoma Treatment and Management?
Oncology Today with Dr. Neil Love, Melanoma Edition: Case Study
Oncology Today with Dr. Neil Love, Melanoma Edition: Evolving Adjuvant Treatment Approaches for Patients With Localized Melanoma
Pearls for Screening and Management of Cutaneous Malignancies
Proceedings from the First Annual Oncology Nursing Retreat
Targeting BRAF/MEK in Melanoma Raises CV Risks

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.